

Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1

EP0725

PURPOSE 1

Alinda M Nyamaizi¹, Imogen Hawley¹, Lebogang Isidoro², Heeran Makkan², Buyisiwe L Dlamini³, Cecilia Milford³, Katherine Gill⁴, Thandeka Nkosi⁴, Nzwakie Mosery⁵, Jennifer Smit⁵, Krishnaveni Reddy⁶, Phumla Sibiyi⁶, Tara McClure⁷, Christoph C Carter⁸, Alexander Kintu⁸, Moupali Das⁸, Elizabeth T Montgomery^{1,9}

¹RTI International, Oakland, CA, USA; ²The Aurum Institute, Rustenburg Clinical Research Centre, Rustenburg, South Africa; ³Centre for the AIDS Programme of Research in South Africa, Vulindlela, South Africa; ⁴The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; ⁵Wits MRU (MatCH Research Unit), Department of Obstetrics and Gynaecology, University of the Witwatersrand, Durban, South Africa; ⁶Wits RHI, Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; ⁷FHI 360, Durham, NC, USA; ⁸Gilead Sciences, Inc., Foster City, CA, USA; ⁹Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, CA, USA

Copies of this poster obtained through QR (Quick Response) are for personal use only and may not be reproduced without written permission of the authors



Conclusions

- A subsample of 13 pregnant and lactating participants from PURPOSE 1 emphasized the benefit of consistent HIV protection—showing that twice-yearly lenacapavir (LEN) injections offer peace of mind without the burden of daily adherence
- All participants emphasized the desire to protect their fetus or infant from acquiring HIV
- However, some participants shared concerns about using an investigational study drug while pregnant or lactating, especially when it was being administered to the abdomen
- There was a willingness amongst participants to continue injections, citing potential availability of an alternative injection site (thigh) as a motivating factor
- These findings underscore the value of education and counseling about the efficacy, safety, tolerability, and pharmacokinetics of twice-yearly LEN for successful pre-exposure prophylaxis (PrEP) implementation among pregnant and lactating participants

Summary

- HIV prevention medication, also known as “PrEP,” helps to lower the chances of someone getting HIV, including for people who are pregnant and lactating
- PrEP is mostly available as a pill, taken by mouth (orally); however, to work effectively, oral PrEP should be taken every day, which many people find hard to do consistently
- LEN is a long-acting type of PrEP that is given as an injection two times a year (every 6 months)
- In a large clinical study called PURPOSE 1, young cisgender women (people who are assigned female at birth) received either a LEN injection two times a year or a pill every day; LEN was very effective in protecting them from getting HIV
- The goal of this substudy was to understand how people who were pregnant and lactating felt about taking pills every day and having an injection two times a year
- People who were pregnant and lactating were willing to take pills or receive an injection, but felt more protected from getting HIV with injections
- It was important to people who were pregnant and lactating that their baby was protected from getting HIV
- These results highlight how important it is to include pregnant and lactating people in studies looking at new medications, such as LEN, and ensure they receive proper education and counseling about how the drug works and behaves in the body to support successful use for HIV prevention

Introduction

- Pregnant and lactating people are disproportionately vulnerable to HIV acquisition^{1,2}
- Daily oral PrEP is highly effective against HIV acquisition if taken as directed.^{3,4} However, uptake of, adherence to, and persistence on PrEP among cisgender women, including pregnant and lactating people, remain suboptimal^{5,6}
- Better understanding of the challenges, barriers, and facilitators associated with much-needed novel PrEP modalities may help to optimize adherence among pregnant and lactating people
- Historically, pregnant and lactating people have been excluded from Phase 3 clinical trials of HIV PrEP, due to safety concerns during pregnancy and lactation, and contraception has been a requirement of participation^{5,7-9}
- PURPOSE 1 (NCT04994509) was the first Phase 3 PrEP trial to support the inclusion of pregnant and lactating participants and demonstrated efficacy and safety of twice-yearly subcutaneous (SC) LEN for PrEP among cisgender young women, including in pregnant and lactating participants¹⁰
 - PURPOSE 1 was implemented before the World Health Organization (WHO) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network toolkit guidelines for the inclusion of pregnant and lactating people, but follows all the recommendations¹¹


Objective

- To explore the acceptability of twice-yearly SC LEN injections and daily oral PrEP in pregnant and lactating participants during the randomized blinded phase of PURPOSE 1

Methods

- PURPOSE 1 was a Phase 3, double-blind, randomized controlled trial evaluating the efficacy and safety of twice-yearly SC LEN, administered primarily in the abdomen, or daily oral emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for PrEP in adolescent girls and young women (**Figure 1**)
- Contraception was provided for free but was not required. Participants who became pregnant were counseled about the benefits and risks and reconsented either to continue on the study drug or to move to the pharmacokinetic tail phase to receive open-label F/TDF
- During the randomized blinded phase, 16 in-depth interviews (IDIs) with 13 pregnant and lactating participants were conducted at five South African substudy sites
 - The majority of interviews (n = 12) were conducted during pregnancy, with four interviews conducted during lactation
 - Three participants were interviewed twice, during both pregnancy and lactation
- Interviews followed a semistructured guide, were audio recorded, and were translated and/or transcribed in English by local qualitative research staff
- Analysis of key issues related to acceptability of twice-yearly subcutaneous LEN or daily oral PrEP during pregnancy and lactation included perceived benefits, barriers, and concerns and was conducted using protocol-defined objectives and IDI topics (**Table 1**). Data were coded in Dedoose™, analyzed thematically, and summarized. Analyses were restricted to IDIs captured prior to the release of data on efficacy and safety of LEN from PURPOSE 1

Figure 1. PURPOSE 1 Study Design



PURPOSE 1 ClinicalTrials.gov: NCT04994509. *The first participant was screened in August 2021, the 50th-percentile participant was randomized in May 2023, and the last participant was randomized in September 2023. [†]Eligibility criteria included: weight ≥ 35 kg, eGFR ≥ 60 mL/min, not pregnant. [‡]n numbers represent the full analysis set for efficacy analyses. [§]Because the randomized blinded phase was stopped early due to an efficacy outcome, the interim analysis served as the primary analysis. [¶]IRR was assessed using a Wald test or likelihood ratio test if there were zero infections. ^{||}¹² IRR was assessed using Poisson regression or an exact conditional Poisson regression model in case of zero infections. eGFR, estimated glomerular filtration rate; F/TAF, emtricitabine/tenofovir alafenamide; F/TDF, emtricitabine/tenofovir disoproxil fumarate; IDI, in-depth interview; IRR, incidence rate ratio; LEN, lenacapavir; PrEP, pre-exposure prophylaxis; SC, subcutaneous.

Table 1. Sample IDI Topics

IDI Topic Focus Areas
- Previous experience of pregnancy prevention and HIV prevention - Motivation to join study - Attitude toward study products - Experience using products during study and while pregnant and lactating - Disclosure of study product use to others
- Community perspectives on pregnant/lactating people using HIV prevention products - Overall satisfaction with study products while pregnant/lactating - Willingness to use study products in the future while pregnant or lactating


IDI, in-depth interview.

Results

Participants

- Although most PURPOSE 1 participants consented to stay on the blinded study drug after becoming pregnant (n/N = 398/487), most pregnant and lactating participants interviewed in this qualitative substudy opted to stop the use of active/placebo injections (n/N = 9/13; **Figure 2**)

Figure 2. Pregnancy Disposition



^a510 pregnancies in 487 participants. ^bParticipants who chose to stop active/placebo injections received daily oral PrEP. PrEP, pre-exposure prophylaxis.

Participants Emphasized the Desire to Protect Themselves and Their Babies From Acquiring HIV

- Compared with twice-yearly LEN injections, participants cited barriers to effective daily oral PrEP, including adherence challenges, side effects, and pill fatigue when combined with prenatal medications
- Participants who preferred daily oral PrEP during pregnancy and lactation cited its established safety, their familiarity with oral PrEP, and the convenience of taking it with prenatal medications




Motivation for Continued Use of LEN Injections During Pregnancy

- Participants appreciated the **convenience** and **reliability** of twice-yearly LEN injections that obviated the need for daily adherence
- Despite the injection site–related pain and discomfort, participants felt **consistently protected**
- Participants who chose to continue LEN injections during pregnancy perceived the blinded injections as **safe and effective** for HIV protection




Participant Interest in Potential Alternative Injection Sites

- Some participants expressed a theoretical interest in future **availability of an alternative injection site (thigh)** as a motivating factor
- The potential use of the thigh as an alternative injection site was well received and seemed to address prior hypothetical concerns about how the use of abdominal injections might impact the infant



Acceptability and Concerns Around LEN Injections During Pregnancy and Lactation

- Participants who preferred daily oral PrEP to twice-yearly LEN injections noted:
 - Unknown safety of the injections during pregnancy and lactation
 - Previous injection-related pain
- Additionally, some participants raised concerns about potential exposure of the study drug to the infant during lactation



Limitations

- The study population included in the current analysis was small. Themes from IDIs from this subset of participants may not represent the attitudes or opinions of other pregnant and lactating participants involved in the PURPOSE 1 study

References: 1. Drake AL, et al. *PLoS Med.* 2014;11:e1001608. 2. Thomson KA, et al. *J Infect Dis.* 2018;218:16-25. 3. Landovitz RJ, et al. *Clin Infect Dis.* 2024;79:1197-207. 4. Marrazzo J, et al. *JAMA.* 2024;331:930-7. 5. Baeten JM, et al. *N Engl J Med.* 2016;375:2121-32. 6. Delany-Moretlwe S, et al. *Lancet Infect Dis.* 2018;18:1241-50. 7. Baeten JM, et al. *N Engl J Med.* 2012;367:399-410. 8. Nel A, et al. *N Engl J Med.* 2016;375:2133-43. 9. Delany-Moretlwe S, et al. *Lancet.* 2022;399:1779-89. 10. Bekker LG, et al. *N Engl J Med.* 2024;391:1179-92. 11. WHO and IMPAACT Network. <https://iris.who.int/bitstream/handle/10665/349842/9789240040182-eng.pdf?sequence=1> (accessed June 24, 2025). 12. Gao F, et al. *Stat Commun Infect Dis.* 2021;13:20200009. 13. Shao Y, Gao F. *Stat Commun Infect Dis.* 2024;16:20230004.

Acknowledgments: We thank all study participants, all participating study investigators, and staff. These studies were funded by Gilead Sciences, Inc. Medical writing support was provided by Simon Wigfield, PhD (Aspire Scientific Ltd, UK), and was funded by Gilead Sciences, Inc.

Disclosures: AMN, IH, LI, HM, BLD, CM, KG, TN, NM, JS, KR, PS, TM, and ETM received research funding from Gilead Sciences, Inc. CCC, AK, and MD are employees of and hold stock in Gilead Sciences, Inc.

Correspondence: Alexander Kintu, alex.kintu@gilead.com.